Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China
Open Access
- 23 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-8
- https://doi.org/10.1186/s12885-020-06724-5
Abstract
Background Pregnancy-associated breast cancer (PABC) is an aggressive disease, and since Chinese authority began to encourage childbearing in 2015, the incidence of PABC has increased. This study investigated the characteristics and survival of PABC patients. Methods Patients with PABC who underwent surgery at Fudan University, Shanghai Cancer Center between 2005 and 2018 were enrolled. Data concerning the tumor characteristics, maternal state (whether first or non-first pregnancy) and survival outcome were recorded. Pearson Chi-square tests were used to compare the characteristics of the tumors, and Kaplan-Meier methods were used to perform the survival analysis. Results Overall, 203 PABC patients were recruited. Since 2015, 65.5% of non-first pregnant women were diagnosed with breast cancer, it's 5.7 fold of the incidence of PABC in non-first pregnant women. No significant differences in tumor characteristics were observed between the patients who were in their first pregnancy and those in non-first pregnancy. Among the entire PABC population, luminal B breast cancer accounted for the largest proportion (38.4%), followed by triple-negative breast cancer (TNBC, 30.0%). The distribution of the molecular subtypes of PABC and non-PABC differed (P < 0.001) as follows: in the PABC patients, Luminal B 38.4%, Triple negative breast cancer (TNBC) 30.1%, Human Epidermal Growth Factor Receptor 2 (HER-2) overexpression 15.8%, and Luminal A 10.8%; in the non-PABC patients, Luminal A 50.9%, Luminal B 20.1%, TNBC 17.4%, and HER-2 overexpression 8.0%. The 3-year disease free survival (DFS) of all PABC patients was 80.3%. The 3-year DFS of the patients in the first-pregnancy group was 78.4%, and that of the patients in the non-first-pregnancy group was 83.7% (P = 0.325). Conclusions Our study proved that the proportion of women who developed PABC during the second or third pregnancy was extremely high relative to the newborn populations. The patients in the PABC population tended to present more luminal B and TNBC breast cancer than the non-PABC patients.Other Versions
Funding Information
- National Natural Science Foundation of China (81602311, 81672601, 81872137)
This publication has 35 references indexed in Scilit:
- Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC)Breast Cancer Research and Treatment, 2013
- Survival Outcomes in Pregnancy Associated Breast Cancer: A Retrospective Case Control StudyThe Breast Journal, 2012
- Breast cancer in pregnancyThe Lancet, 2012
- Increased Mortality in Women with Breast Cancer Detected during Pregnancy and Different Periods PostpartumCancer Epidemiology, Biomarkers & Prevention, 2011
- Breast cancer during pregnancyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled StudyThe Breast Journal, 2009
- The impact of pregnancy on breast cancer outcomes in women ≤35 yearsCancer, 2009
- Evidence of Poorer Survival in Pregnancy-Associated Breast CancerObstetrics & Gynecology, 2008
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in uteroCancer, 2006